Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed.